CN113195084B - 可用作分子伴侣介导的自噬调节剂的苯并噁唑及相关化合物 - Google Patents

可用作分子伴侣介导的自噬调节剂的苯并噁唑及相关化合物 Download PDF

Info

Publication number
CN113195084B
CN113195084B CN201980081709.XA CN201980081709A CN113195084B CN 113195084 B CN113195084 B CN 113195084B CN 201980081709 A CN201980081709 A CN 201980081709A CN 113195084 B CN113195084 B CN 113195084B
Authority
CN
China
Prior art keywords
chlorobenzo
oxazol
phenyl
compound
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980081709.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN113195084A (zh
Inventor
安娜·玛利亚·奎尔沃
埃夫里皮迪思·加瓦肖蒂斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of CN113195084A publication Critical patent/CN113195084A/zh
Application granted granted Critical
Publication of CN113195084B publication Critical patent/CN113195084B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980081709.XA 2018-10-10 2019-10-10 可用作分子伴侣介导的自噬调节剂的苯并噁唑及相关化合物 Active CN113195084B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862743920P 2018-10-10 2018-10-10
US62/743,920 2018-10-10
PCT/US2019/055493 WO2020077024A1 (en) 2018-10-10 2019-10-10 Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators

Publications (2)

Publication Number Publication Date
CN113195084A CN113195084A (zh) 2021-07-30
CN113195084B true CN113195084B (zh) 2024-04-09

Family

ID=70163886

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980081709.XA Active CN113195084B (zh) 2018-10-10 2019-10-10 可用作分子伴侣介导的自噬调节剂的苯并噁唑及相关化合物

Country Status (11)

Country Link
US (1) US12473266B2 (cg-RX-API-DMAC7.html)
EP (1) EP3863755A4 (cg-RX-API-DMAC7.html)
JP (1) JP7503850B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210082466A (cg-RX-API-DMAC7.html)
CN (1) CN113195084B (cg-RX-API-DMAC7.html)
AU (1) AU2019358074A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006843A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115297A1 (cg-RX-API-DMAC7.html)
IL (1) IL282069A (cg-RX-API-DMAC7.html)
MX (1) MX2021004134A (cg-RX-API-DMAC7.html)
WO (1) WO2020077024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022015624A1 (en) * 2020-07-16 2022-01-20 Schrödinger, Inc. Substituted dihydropyrazinediones as modulators of the nmda receptor
JP2023551435A (ja) * 2020-11-20 2023-12-08 エフ. ホフマン-ラ ロシュ アーゲー B型肝炎ウイルス感染症の処置及び予防のためのn置換4-(1,3-アリールオキサゾロ-2-イル)フェニル化合物
WO2022155333A1 (en) * 2021-01-13 2022-07-21 Albert Einstein College Of Medicine Use of chaperone-mediated autophagy activators for treating or preventing blood cancers and myelodysplastic syndromes
EP4326267A4 (en) * 2021-04-21 2025-07-09 Albert Einstein College Medicine METHOD FOR INCREASING CHAPERONE-MEDIATED AUTOPHAGY BY STABILIZING THE INTERACTION BETWEEN THE RETINOIC ACID RECEPTOR ALPHA AND AN INHIBITOR
KR102778740B1 (ko) 2021-06-24 2025-03-07 주식회사 엘지화학 합성가스의 제조방법
CN114404421B (zh) * 2022-02-28 2023-04-28 同济大学 选择性自噬激活剂qx77在制备干预或治疗糖尿病视网膜病变的药物中的应用
WO2024225738A1 (ko) * 2023-04-25 2024-10-31 부산대학교 산학협력단 지방간질환 치료 또는 예방 목적의 fxr/ppar alpha 이중 작용 활성을 가지는 벤즈옥사졸 유도체 화합물

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1137033A (en) * 1966-01-07 1968-12-18 Ciba Ltd Benzoxazole derivatives and their use as scintillators
US5428052A (en) * 1984-09-19 1995-06-27 Centre Internationale De Recherches Dermatologiques (C.I.R.D.) Aromatic heterocyclic derivatives and their therapeutic and cosmetic use
CA2237752C (en) * 1995-11-17 2006-05-16 Sibia Neurosciences, Inc. Novel substituted aryl compounds useful as modulators of acetylcholine receptors
CN101420950A (zh) * 2006-02-10 2009-04-29 萨米特公开有限公司 杜兴肌营养不良的治疗
RU2008136371A (ru) * 2006-02-10 2010-03-20 САММИТ КОРПОРЕЙШН ПиЭлСи (GB) Лечение миодистрофии дюшена
US8518980B2 (en) * 2006-02-10 2013-08-27 Summit Corporation Plc Treatment of Duchenne muscular dystrophy
WO2017114863A1 (en) * 2015-12-30 2017-07-06 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2017160116A2 (ko) * 2016-03-17 2017-09-21 연세대학교 산학협력단 니코틴아미드 포스포리보실트랜스퍼라제 억제용 신규 화합물 및 이를 포함하는 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365892A1 (en) * 2001-11-30 2003-06-17 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
KR20040096601A (ko) 2002-02-21 2004-11-16 시바 스페셜티 케미칼스 홀딩 인크. 락탐계 안료 및 착색된 플라스틱 또는 중합체성 착색입자의 제조시 이의 용도
JP4903133B2 (ja) 2004-04-30 2012-03-28 ジェネンテック,インコーポレイティド ヘッジホッグシグナル伝達のキノキサリン阻害剤
UA91341C2 (ru) * 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
EP1954287B2 (en) 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
MX2011002647A (es) 2008-09-23 2011-04-07 Wista Lab Ltd Ligandos para moleculas tau agregadas.
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する2−アリールベンゾオキサゾール化合物
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
JP2018087173A (ja) 2016-11-29 2018-06-07 国立大学法人北海道大学 悪性脳腫瘍治療薬
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1137033A (en) * 1966-01-07 1968-12-18 Ciba Ltd Benzoxazole derivatives and their use as scintillators
US5428052A (en) * 1984-09-19 1995-06-27 Centre Internationale De Recherches Dermatologiques (C.I.R.D.) Aromatic heterocyclic derivatives and their therapeutic and cosmetic use
CA2237752C (en) * 1995-11-17 2006-05-16 Sibia Neurosciences, Inc. Novel substituted aryl compounds useful as modulators of acetylcholine receptors
CN101420950A (zh) * 2006-02-10 2009-04-29 萨米特公开有限公司 杜兴肌营养不良的治疗
RU2008136371A (ru) * 2006-02-10 2010-03-20 САММИТ КОРПОРЕЙШН ПиЭлСи (GB) Лечение миодистрофии дюшена
US8518980B2 (en) * 2006-02-10 2013-08-27 Summit Corporation Plc Treatment of Duchenne muscular dystrophy
WO2017114863A1 (en) * 2015-12-30 2017-07-06 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2017160116A2 (ko) * 2016-03-17 2017-09-21 연세대학교 산학협력단 니코틴아미드 포스포리보실트랜스퍼라제 억제용 신규 화합물 및 이를 포함하는 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Aerobic oxidation of alcohols and the synthesis of benzoxazoles catalyzed by a cuprocupric coordination polymer (Cu+-CP) assisted by tempo";Feng Xun等;《Inorganic Chemistry》;20150302;第54卷(第5期);第2088-2090页 *
Li Qian等."Autophagy and alzheimer's disease".《Cellular and Molecular Neurobiology》.2017,第第37卷卷(第第3期期),第377-388页. *

Also Published As

Publication number Publication date
MX2021004134A (es) 2021-07-16
AU2019358074A1 (en) 2021-05-06
JP2022504650A (ja) 2022-01-13
US12473266B2 (en) 2025-11-18
CA3115297A1 (en) 2020-04-16
IL282069A (en) 2021-05-31
JP7503850B2 (ja) 2024-06-21
KR20210082466A (ko) 2021-07-05
CN113195084A (zh) 2021-07-30
EP3863755A4 (en) 2022-08-03
BR112021006843A2 (pt) 2021-07-13
US20210387953A1 (en) 2021-12-16
EP3863755A1 (en) 2021-08-18
WO2020077024A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
JP7503850B2 (ja) シャペロン介在性オートファジー調節剤として有用なベンゾオキサゾールおよび関連化合物
DE60022906T2 (de) Heterozyklische verbindungen mit sulfonamid-gruppen
TWI448288B (zh) 新穎化合物及其等之用途
EP2021327B1 (en) Antidiabetic bicyclic compounds
AU2022201709B2 (en) Mono-(acid) salts of 6-aminoisoquinolines and uses thereof
JP7262141B2 (ja) シャペロン介在性オートファジー調節剤として有用な化合物
JP2020506940A (ja) Oga阻害化合物
HRP20000804A2 (en) Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline
JP2013522364A (ja) 置換イミダゾ[1,2−b]ピリダジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用の方法
AU2005303904A1 (en) Azaindole carboxamides
TW201625533A (zh) Kcnq 2至5通道活化劑
KR20250051780A (ko) (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산의합성을 위한 공정
CN103037693A (zh) 作为mglur5正向变构调节剂的取代的6-甲基烟酰胺
EP3442967A1 (en) Novel n-[(pyrimidinyloxy)propanyl]benzamides
KR20220118483A (ko) Oga 억제제 화합물
US9255090B2 (en) Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
CA3102903A1 (en) Oga inhibitor compounds
CN112313218A (zh) Oga抑制剂化合物
US20260116889A1 (en) Macrocyclic pyrimidine derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of neurodegenerative disease containing same as active ingredient
EP1798220A1 (en) Dibenzene derivatives as calcium channel blockers
KR20080075922A (ko) 칼슘 채널 차단제로서의 디벤젠 유도체
JP2018508544A (ja) 選択的bace1阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant